PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
44.40
+0.48 (+1.09%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close43.92
Open44.14
Bid0.00 x 900
Ask0.00 x 2900
Day's Range43.07 - 44.56
52 Week Range33.20 - 46.47
Volume24,846,171
Avg. Volume22,593,843
Market Cap256.653B
Beta (3Y Monthly)0.75
PE Ratio (TTM)11.21
EPS (TTM)3.96
Earnings DateJan 28, 2019 - Feb 1, 2019
Forward Dividend & Yield1.36 (3.02%)
Ex-Dividend Date2018-11-08
1y Target Est44.59
Trade prices are not sourced from all markets
  • Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
    Zacks10 hours ago

    Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Pfizer (PFE) closed at $44.40, marking a +1.09% move from the previous day.

  • How Endo International’s Gross Margin Has Trended
    Market Realist12 hours ago

    How Endo International’s Gross Margin Has Trended

    Endo International’s (ENDP) next two business segments are: The US Generic Pharmaceuticals segment includes solid oral extended release, solid oral immediate release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, and sprays. Revenues from this segment declined from $294.75 million in the third quarter of 2017 to $257.97 million in the third quarter of 2018. The International Pharmaceuticals segment revenues also declined from $56.43 million in the third quarter of 2017 to $30.25 million in the third quarter of 2018.

  • InvestorPlace18 hours ago

    PFE Stock Has Broken Its Slump and Could Challenge Former Highs

    Pfizer (NYSE:PFE) may find itself doing something it has not done in years—break records. The New York-based pharmaceutical giant found itself stuck as PFE stock spent years mired in a trading range. Now it looks poised to reach and surpass the highs that have eluded Pfizer for almost two decades.

  • MarketWatch17 hours ago

    Generic drug makers stocks fall sharply after report of expanded price-fixing probe

    Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing. The case now involves at least 16 companies and 300 drugs, the report said, citing Joseph Nielsen, an assistant attorney general and antitrust investigator in Connecticut, who has been a leader in the probe. Nielsen is quoted as saying, "this is most likely the largest cartel in the history of the United States." The victims were consumers and taxpayers, who have been carrying the high cost of overcharges on common antiboitics, blood-pressure medications, arthritis treatments, anxiety pills and more, said the report. Teva Pharmaceuticals Industries Ltd. ADRs fell 5.7% on the news. Mylan NV was down 4.6%, and Dr. Reddy Labs Ltd was down 3%. Abbott Labs was down 1.4% and Pfizer Inc. was down 1.6%. The S&P 500 was down 1.8% and the Dow Jones Industrial Average was down about 2%.

  • Zacks Small Cap Research18 hours ago

    ATRS: Xyosted & Epi Pen Available for Sale

    The last week of November was a good one for Antares Pharma, Inc. (ATRS) with both Epi Pen and Xyosted now commercially available. Teva Pharmaceuticals (TEVA) announced on November 27th that the recently approved AB-rated generic Epinephrine Pen is now available in the United States. For the remainder of 2018, only the Epi Pen 0.3 mg version will be available in limited quantities with additional supply of the 0.3 mg version and Epi Pen Jr (0.15 mg) to be available in 2019.

  • Stock Market Power Rankings: Amazon Takes Control
    Motley Foolyesterday

    Stock Market Power Rankings: Amazon Takes Control

    They're big, beautiful, and ranked from 1 to 50.

  • Is Pfizer Inc. (PFE) A Good Stock To Buy According To Hedge Funds?
    Insider Monkey2 days ago

    Is Pfizer Inc. (PFE) A Good Stock To Buy According To Hedge Funds?

    Before we spend many hours researching a company, we’d like to analyze what insiders, hedge funds and billionaire investors think of the stock first. We would like to do so because the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of […]

  • Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
    Zacks5 days ago

    Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study

    Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.

  • Peninsula drug maker to pay $360M to settle Justice Department claims
    American City Business Journals4 days ago

    Peninsula drug maker to pay $360M to settle Justice Department claims

    The company gave a nonprofit foundation money to cover Medicare copays for its pulmonary arterial hypertension drugs as it hiked the prices of those drugs and steered Medicare patients away from the company's own free drug program to the foundation.

  • Investing.com5 days ago

    Pfizer Falls 3%

    Investing.com - Pfizer (NYSE:PFE) fell by 3.10% to trade at $43.74 by 11:25 (16:25 GMT) on Thursday on the NYSE exchange.

  • Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx
    Zacks5 days ago

    Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx

    Exelixis (EXEL) and its partner announce initiation of a pivotal study to evaluate its kidney cancer drug, Cabometyx, in combination with Roche's Tecentriq in liver cancer.

  • CNBC5 days ago

    Four stocks have avoided the market crush to hit new highs

    Health-care stocks have found new life as markets crater. UnitedHealth UNH and Eli Lilly LLY roared to record highs on Tuesday, while Pfizer PFE and Merck MRK moved to their highest levels since 2001, although they were all down at least 1 percent in Thursday's premarket. Mark Newton , technical analyst at Newton Advisors, said Tuesday the overall health-care trade still looks like a solid play.

  • China's Drugmakers Plunge Most Since 2009 on Price Concerns
    Bloomberg5 days ago

    China's Drugmakers Plunge Most Since 2009 on Price Concerns

    CSPC Pharmaceutical Group Ltd., which is bidding to provide drugs to Chinese cities in the program, tumbled 14 percent at the close in Hong Kong Thursday, its biggest decline since 2008. The MSCI China Health Care Index fell 8.4 percent, the biggest decline since 2009.

  • ACCESSWIRE6 days ago

    Today's Research Reports on Trending Tickers: Pfizer and Merck & Co.

    NEW YORK, NY / ACCESSWIRE / December 5, 2018 / U.S. equities plunged on Tuesday as skepticism over the U.S. and China’s ability to close a trade agreement weighed on the markets. The Dow Jones Industrial ...

  • Pfizer (PFE) Stock Moves -1.78%: What You Should Know
    Zacks6 days ago

    Pfizer (PFE) Stock Moves -1.78%: What You Should Know

    Pfizer (PFE) closed the most recent trading day at $45.17, moving -1.78% from the previous trading session.

  • How IBM Is Investing in AI Solutions
    Market Realist7 days ago

    How IBM Is Investing in AI Solutions

    AI is the buzzword these days, and the market has huge growth potential. PR Newswire, citing QY Research, reported that the global AI market could grow 52.6% (compounded annually) from $2.65 billion in 2017 to $78 billion by 2025. IBM (IBM) has been the largest player in the AI market.

  • 3 Big Pharma Stocks Hitting 52-Week Highs -- Are They Buys?
    Motley Fool7 days ago

    3 Big Pharma Stocks Hitting 52-Week Highs -- Are They Buys?

    Could big wins for these big pharma stocks in 2018 translate to more big returns?

  • Monday’s Vital Data: Pfizer, Goldman Sachs and Caterpillar
    InvestorPlace8 days ago

    Monday’s Vital Data: Pfizer, Goldman Sachs and Caterpillar

    U.S. stock futures and options trading volume are galloping higher following a promising turn in the trade war. During their meeting at the G-20 summit over the weekend, President Donald Trump and Chinese president Xi Jinping agreed to halt additional tariffs after Jan. 1.

  • Zacks Small Cap Research8 days ago

    DARE: Ovaprene PCT Continues. TS Content Validity Study, Thermographic Study Underway

    By Brian Marckx, CFA NASDAQ:DARE READ THE FULL DARE RESEARCH REPORT Q3 / Pipeline Update Daré (NASDAQ:DARE) reported financial results for their third quarter and provided an operational update. Relative ...

  • AbbVie Settles With Pfizer for Humira Biosimilar in U.S.
    Zacks8 days ago

    AbbVie Settles With Pfizer for Humira Biosimilar in U.S.

    AbbVie (ABBV) strikes a deal with Pfizer to launch its biosimilar of Humira in the United States in November

  • Business Wire8 days ago

    Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting

    NEW YORK-- -- 26-week data from the ongoing 52-week REFLECTIONS B328-06 study met its primary endpoint, demonstrating comparable safety and efficacy for patients with indolent follicular lymphoma The U.S. Food and Drug Administration accepted for review, a Biologics License Application for PF-05280586 in September 2018 Pfizer Inc. announced today at the American Society of Hematology Annual Meeting ...

  • Morningstar10 days ago

    Delayed Humira Biosimilar Boosts AbbVie's Fair Value

    Pfizer won't be able to access the U.S. market with its biosimilar version until late 2023, providing AbbVie with additional years of exclusivity and strong cash flows.

  • Barrons.com10 days ago

    U.S. Stocks Sprint Ahead to End a Blockbuster Week

    U.S. stocks rallied Friday afternoon, leaving all three major indexes with weekly gains of about 5%.